These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15177479)

  • 1. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
    Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
    Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
    J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
    Townes JA; Golebiowski A; Clark MP; Laufersweiler MJ; Brugel TA; Sabat M; Bookland RG; Laughlin SK; VanRens JC; De B; Hsieh LC; Xu SC; Janusz MJ; Walter RL
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4945-8. PubMed ID: 15341957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor.
    Kim DK; Kim J; Park HJ
    Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Dewang PM; Kim DK
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4228-32. PubMed ID: 20621731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of [2-(4-quinolyloxy)phenyl]methanone derivatives: novel selective inhibitors of transforming growth factor-beta kinase.
    Shimizu T; Kimura K; Sakai T; Kawakami K; Miyazaki T; Nakouji M; Ogawa A; Ohuchi H; Shimizu K
    J Med Chem; 2008 Jun; 51(11):3326-9. PubMed ID: 18479116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
    Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
    J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
    Li X; Wang L; Long L; Xiao J; Hu Y; Li S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.